Lucid Diagnostics Inc. has successfully raised approximately $15 million through the sale of its newly designated Series C Convertible Preferred Stock. This funding, facilitated through subscription agreements with accredited investors, is a strategic move aimed at supporting the company's growth initiatives in the surgical and medical instruments sector.
The Series C offering, which involved the sale of 15,000 shares at a price of $1,000 per share, closed on October 21, 2026. The funds raised are expected to bolster Lucid Diagnostics' operational capabilities and enhance its market position.
Background
Lucid Diagnostics Inc. operates under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. The company is listed on the Nasdaq under the ticker symbol LUCD. As an emerging growth company, Lucid Diagnostics has been active in filing various reports with the SEC, including recent 8-K forms detailing significant corporate events.
What the Filing Says
According to the SEC filing (accession number 0001493152-26-048114), the Series C Convertible Preferred Stock is convertible into common stock at the option of the holder. The initial conversion price is set at $0.3519, subject to adjustments based on market conditions. The filing also specifies that the preferred stock will carry a 20% annual dividend, payable in shares of common stock.
Impact
This fundraising effort may positively impact Lucid Diagnostics' ability to expand its product offerings and enhance its competitive edge in the medical instruments market. Investors and stakeholders may view this capital raise as a sign of the company's commitment to growth and innovation.
What's Next
The filing does not specify what happens next for Lucid Diagnostics following this capital raise, but the funds are likely to be allocated towards strategic initiatives aimed at enhancing the company's market presence.